<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">DOXYCYCLINE HYCLATE</span><br/>(dox-i-sye'kleen)<br/><span class="topboxtradename">Adoxa, </span><span class="topboxtradename">Apo-Doxy <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Doryx, </span><span class="topboxtradename">Doxy, </span><span class="topboxtradename">Doxy-Caps, </span><span class="topboxtradename">Doxychel, </span><span class="topboxtradename">Doxycin <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Doxy-Lemmon, </span><span class="topboxtradename">Monodox, </span><span class="topboxtradename">Novodoxylin <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">SK-Doxycycline, </span><span class="topboxtradename">Vibramycin, </span><span class="topboxtradename">Vibra-Tabs, </span><span class="topboxtradename">Vivox<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antibiotic</span>; <span class="classification">tetracycline</span><br/><b>Prototype: </b>Tetracycline<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>50 mg, 75 mg, 100 mg capsules, tablets; 200 mg injection</p>
<h1><a name="action">Actions</a></h1>
<p>Semisynthetic broad-spectrum tetracycline antibiotic derived from oxytetracycline. More completely absorbed with effective
         blood levels maintained for longer periods and excreted more slowly than most other tetracyclines. Thus it requires smaller
         and less frequent dosing.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Primarily bacteriostatic in effect. Similar in use to tetracycline (e.g., effective against <i>chlamydial</i> and <i>mycoplasmal</i> infections; gonorrhea, syphilis, rickettsia).
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Similar to those of tetracycline, e.g., chlamydial and mycoplasmal infections; gonorrhea, syphilis in penicillin-allergic
         patients; rickettsial diseases; acute exacerbations of chronic bronchitis.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Treatment of acute PID, leptospirosis, prophylaxis for rape victims, suppression and chemoprophylaxis of chloroquine-resistant
         <i>Plasmodium falciparum</i> malaria, short-term prophylaxis and treatment of travelers' diarrhea caused by enterotoxigenic strains of <i>Escherichia coli</i>. Intrapleural administration for malignant pleural effusions.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Sensitivity to any of the tetracyclines; use during period of tooth development including last half of pregnancy (category
         D), lactation, infants, and children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Alcoholism.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Antiinfective</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO/IV</span> 100 mg q12h on day 1, then 100 mg/d as single dose (max: 100 mg q12h)<br/><span class="rdage">Child:</span> <span class="rdroute">PO/IV</span>
<i>&gt;8 y</i>, 4.4 mg/kg in 12 doses on day 1, then 2.24.4 mg/kg/d in 12 divided doses<br/><br/><span class="indicationtitle">Gonorrhea</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 200 mg immediately, followed by 100 mg h.s., then 100 mg b.i.d. for 3 d<br/><br/><span class="indicationtitle">Primary and Secondary Syphilis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 300 mg/d in divided doses for at least 10 d<br/><br/><span class="indicationtitle">Travelers' Diarrhea</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 100 mg/d during risk period (up to 2 wk) beginning day 1 of travel<br/><br/><span class="indicationtitle">Acne</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 100 mg q12h on day 1, then 100 mg q.d.<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>&gt;8 y and &gt;45 kg,</i> 100 mg q12h on day 1, then 100 mg q.d.; <i>&gt;8 y and , 2.2 mg/kg q12h day 1 then 2.2 mg/kg/q.d.<br/></i></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Check expiration date. Degradation products of tetracycline are toxic to the kidneys.</li>
<li>Give with food or a full glass of milk to minimize nausea without significantly affecting bioavailability of drug (<small>UNLIKE MOST TETRACYCLINES</small>).
         </li>
<li>Consult physician about ordering the oral suspension for patients who are bedridden or have difficulty swallowing.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype"> Intermittent/Continuous:</span>  Reconstitute by adding 10 mL sterile water for injection, or D5W, NS, LR, D5/LR, or other diluent recommended by manufacturer,
                  to each 100 mg of drug. Further dilute with 1001000 mL (per 100 mg of drug) of compatible infusion solution to produce concentrations ranging
                  from 0.1 to 1 mg/mL. 
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> Intermittent/</span><span class="methodtype">Continuous:</span>  IV infusion rate will usually be prescribed by physician. Duration of infusion varies with dose but is usually 14 h. Recommended minimum infusion time for 100 mg of 0.5 mg/mL solution is 1 h. Infusion should be completed within 12 h of dilution. When diluted with LR or D5/LR, infusion must be completed within 6 h to ensure adequate stability. Protect all solutions from direct sunlight during infusion. 
               </p>
</td>
</tr>
</table>
<ul>
<li>Store oral and parenteral forms (prior to reconstitution) in tightly covered, light-resistant containers at 15°30°
            C (59°86° F) unless otherwise directed.
         </li>
<li>Refrigerate reconstituted solutions for up to 72 h. After this time, infusion must be completed within 12 h.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Special Senses:</span> Interference with color vision. <span class="typehead">GI:</span> Anorexia, <span class="speceff-common">nausea,</span> vomiting, diarrhea, enterocolitis; esophageal irritation (oral capsule and tablet). <span class="typehead">Skin:</span> Rashes, photosensitivity reaction. <span class="typehead">Other:</span> Thrombophlebitis (IV use), superinfections. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Like other <span class="alt">tetracyclines,</span> doxycycline may cause false increases in <span class="alt">urinary catecholamines</span> (fluorometric methods); false decreases in <span class="alt">urinary urobilinogen;</span> false-negative <span class="alt">urine glucose</span> with <span class="alt">glucose oxidase methods</span> (e.g., <span class="alt">Clinistix,</span>
<span class="alt">TesTape</span>); parenteral doxycycline (containing ascorbic acid) may cause false-positive determinations using <span class="alt">Benedict's reagent</span> or <span class="alt">Clinitest.</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span>
<span class="classification"> antacids</span>, <b>iron</b> preparation, <b>calcium,</b>
<b>magnesium,</b>
<b>zinc,</b>
<b>kaolin-pectin,</b>
<b>sodium bicarbonate</b> can significantly decrease absorption; effects of both doxycycline and <b>desmopressin</b> antagonized; increases <b>digoxin</b> absorption, thus increasing risk of <b>digoxin</b> toxicity; <b>methoxyflurane</b> increases risk of renal failure. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Completely absorbed from GI tract. <span class="typehead">Peak:</span> 1.54 h. <span class="typehead">Distribution:</span> Penetrates eye, prostate, and CSF; crosses placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Not metabolized. <span class="typehead">Elimination:</span> 2030% excreted in urine and 2040% in feces in 48 h. <span class="typehead">Half-Life:</span> 1424 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Report sudden onset of painful or difficult swallowing promptly to physician. Doxycycline (capsule and tablet forms) is associated
            with a comparatively high incidence of esophagitis, especially in patients &gt;40 y.
         </li>
<li>Report evidence of superinfections (see Appendix F).</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Take capsule or tablet forms with a full glass (240 mL) of water to ensure passage into stomach and prevent esophageal ulceration.
            Avoid taking capsule or tablet within 1 h of lying down or retiring.
         </li>
<li>Avoid exposure to direct sunlight and ultraviolet light during and for 4 or 5 d after therapy is terminated to reduce risk
            of phototoxic reaction. Phototoxic reaction appears like an exaggerated sunburn. Sunscreens provide little protection.
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>